The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial
Open accessAbstract
Importance: Optimizing radiation therapy techniques for localized prostate cancer can affect patient outcomes. Dose escalation improves biochemical control, but no prior trials were powered to detect overall survival (OS) differences. Objective: To determine whether radiation dose escalation to 79.2 Gy compared with 70.2 Gy would improve OS and other outcomes in prostate cancer. Design, Setting, and Participants: The NRG Oncology/RTOG 0126 randomized clinical trial randomized 1532 patients from 104 North American Radiation Therapy Oncology Group institutions March 2002 through August 2008. Men with stage cT1b to T2b, Gleason score 2 to 6, and prostate-specific antigen (PSA) level of 10 or greater and less than 20 or Gleason score of 7 and PSA less than 15 received 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy to 79.2 Gy in 44 fractions or 70.2 Gy in 39 fractions. Main Outcomes and Measures: Time to OS measured from randomization to death due to any cause. American Society for Therapeutic Radiology and Oncology (ASTRO)/Phoenix definitions were used for biochemical failure. Acute (≤90 days of treatment start) and late radiation therapy toxic effects (>90 days) were graded using the National Cancer Institute Common Toxicity Criteria, version 2.0, and the RTOG/European Organisation for the Research and Treatment of Cancer Late Radiation Morbidity Scoring Scheme, respectively. Results: With a median follow-up of 8.4 (range, 0.02-13.0) years in 1499 patients (median [range] age, 71 [33-87] years; 70% had PSA <10 ng/mL, 84% Gleason score of 7, 57% T1 disease), there was no difference in OS between the 751 men in the 79.2-Gy arm and the 748 men in the 70.2-Gy arm. The 8-year rates of OS were 76% with 79.2 Gy and 75% with 70.2 Gy (hazard ratio [HR], 1.00; 95% CI, 0.83-1.20; P = .98). The 8-year cumulative rates of distant metastases were 4% for the 79.2-Gy arm and 6% for the 70.2-Gy arm (HR, 0.65; 95% CI, 0.42-1.01; P = .05). The ASTRO and Phoenix biochemical failure rates at 5 and 8 years were 31% and 20% with 79.2 Gy and 47% and 35% with 70.2 Gy, respectively (both P < .001; ASTRO: HR, 0.59; 95% CI, 0.50-0.70; Phoenix: HR, 0.54; 95% CI, 0.44-0.65). The high-dose arm had a lower rate of salvage therapy use. The 5-year rates of late grade 2 or greater gastrointestinal and/or genitourinary toxic effects were 21% and 12% with 79.2 Gy and 15% and 7% with 70.2 Gy (P = .006 [HR, 1.39; 95% CI, 1.10-1.77] and P = .003 [HR, 1.59; 95% CI, 1.17-2.16], respectively). Conclusions and Relevance: Despite improvements in biochemical failure and distant metastases, dose escalation did not improve OS. High doses caused more late toxic effects but lower rates of salvage therapy. Trial Registration: clinicaltrials.gov Identifier: NCT00033631.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849 · cited 1×
“0) years in 1499 patients (median [range] age, 71 [33-87] years; 70% had PSA <10 ng/mL, 84%Gleason score of 7, 57% T1 disease), there was no difference in OS between the 751 men in the 79.”
BackgroundA Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
Roach, M., Hanks, G., Thames, H., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.04.029 · Cited by 2,749
Self-citation10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
The statistical analysis of failure time data
Herson, J. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90009-x · Cited by 1,380
Brookes, A. J. (1999) · Gene · doi:10.1016/s0378-1119(99)00219-x · Cited by 1,377
Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer
Kuban, D. A., Tucker, S. L., Dong, L., Starkschall, G., Huang, E. H., Cheung, M. R., Lee, A. K., & Pollack, A. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.054 · Cited by 1,232
Consensus statement: Guidelines for PSA following radiation therapy1
AMERICANSOCIETYFORTHERAPEUTICR (1997) · International Journal of Radiation OncologyBiologyPhysics · doi:10.1016/s0360-3016(97)00002-3 · Cited by 1,151
Morris, W. J., Tyldesley, S. K., Rodda, S. L., Halperin, R. M., Pai, H. H., McKenzie, M. R., Duncan, G. G., Morton, G., Hamm, J., & Murray, N. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.11.026 · Cited by 753
Self-citationZietman, A. L., Bae, K., Slater, J. D., Shipley, W. U., Efstathiou, J. A., Coen, J. J., Bush, D. A., Lunt, M., Spiegel, D. Y., Skowronski, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8475 · Cited by 735
D'Amico, A. V., Whittington, R., Malkowicz, S. B., Schultz, D., Blank, K., Broderick, G. A., Tomaszewski, J. E., Renshaw, A. A., Kaplan, I., Beard, C. J., et al. (1999) · Journal of Urology · doi:10.1016/s0022-5347(01)61700-2 · Cited by 713
Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer
Jones, C. U., Hunt, D., McGowan, D. G., Amin, M. B., Chetner, M. P., Bruner, D. W., Leibenhaut, M. H., Husain, S. M., Rotman, M., Souhami, L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012348 · Cited by 696
Self-citationAndrogen Suppression and Radiation vs Radiation Alone for Prostate Cancer: A Randomized Trial
D’Amico, A. V., Chen, M.-H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008) · JAMA · doi:10.1001/jama.299.3.289 · Cited by 690
The randomization and stratification of patients to clinical trials
Zelen, M. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90015-0 · Cited by 613
Gaynor, J. J., Feuer, E. J., Tan, C. C., Wu, D. H., Little, C. R., Straus, D. J., Clarkson, B. D., & Brennan, M. F. (1993) · Journal of the American Statistical Association · doi:10.1080/01621459.1993.10476289 · Cited by 483
Dearnaley, D. P., Jovic, G., Syndikus, I., Khoo, V., Cowan, R. A., Graham, J. D., Aird, E. G., Bottomley, D., Huddart, R. A., Jose, C. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70040-3 · Cited by 463
70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial
Beckendorf, V., Guerif, S., Le Prisé, E., Cosset, J.-M., Bougnoux, A., Chauvet, B., Salem, N., Chapet, O., Bourdain, S., Bachaud, J.-M., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.03.049 · Cited by 452
Zelefsky, M. J., Cowen, D., Fuks, Z., Shike, M., Burman, C., Jackson, A., Venkatramen, E. S., & Leibel, S. A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990601)85:11<2460::aid-cncr23>3.0.co;2-n · Cited by 336
Talcott, J. A., Rieker, P., Clark, J. A., Propert, K. J., Weeks, J. C., Beard, C. J., Wishnow, K. I., Kaplan, I., Loughlin, K. R., Richie, J. P., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.275 · Cited by 323
Michalski, J. M., Yan, Y., Watkins-Bruner, D., Bosch, W. R., Winter, K., Galvin, J. M., Bahary, J.-P., Morton, G. C., Parliament, M. B., & Sandler, H. M. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.07.041 · Cited by 312
Self-citationOn life satisfaction in male erectile dysfunction
Fugl-Meyer, A., Lodnert, G., Bränholm, I.-B., & Fugl-Meyer, K. (1997) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900269 · Cited by 276
Ovesen, L., Allingstrup, L., Hannibal, J., Mortensen, E. L., & Hansen, O. P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.2043 · Cited by 271
Sex or survival: trade-offs between quality and quantity of life.
Singer, P. A., Tasch, E. S., Stocking, C., Rubin, S., Siegler, M., & Weichselbaum, R. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.2.328 · Cited by 225
Improved methodology for analyzing local and distant recurrence.
Gelman, R., Gelber, R., Henderson, I. C., Coleman, C. N., & Harris, J. R. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.3.548 · Cited by 224
Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes
Andreassen, C. N., Alsner, J., Overgaard, M., & Overgaard, J. (2003) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2003.09.010 · Cited by 217
Radiation-Associated Impotence: A Clinical Study of Its Mechanism
Goldstein, I. (1984) · JAMA · doi:10.1001/jama.1984.03340310017012 · Cited by 163
Damaraju, S., Murray, D. L., Dufour, J. H., Carandang, D., Myrehaug, S. D., Fallone, B. G., Field, C., Greiner, R., Hanson, J., Cass, C. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2703 · Cited by 143
Self-citationAndreassen, C. N., Alsner, J., Overgaard, J., Herskind, C., Haviland, J., Owen, R., Homewood, J., Bliss, J. M., & Yarnold, J. R. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2004.12.012 · Cited by 135
Single nucleotide polymorphisms: From the evolutionary past. . .
Stoneking, M. (2001) · Nature · doi:10.1038/35057279 · Cited by 124
Can the Spitzer Quality of Life Index help to reduce prognostic uncertainty in terminal care?
Addington-Hall, J., Macdonald, L., & Anderson, H. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.360 · Cited by 117
Andreassen, C. N., Overgaard, J., Alsner, J., Overgaard, M., Herskind, C., Cesaretti, J. A., Atencio, D. P., Green, S., Formenti, S. C., Stock, R. G., et al. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.09.014 · Cited by 106
Kupelian, P. A., Mohan, D. S., Lyons, J. A., Klein, E. A., & Reddy, C. A. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00455-1 · Cited by 101
Cesaretti, J. A., Stock, R. G., Lehrer, S. P., Atencio, D. A., Bernstein, J. L., Stone, N. N., Wallenstein, S. R., Green, S., Loeb, K., Kollmeier, M. A., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.09.031 · Cited by 99
A general inefficacy interim monitoring rule for randomized clinical trials
Freidlin, B., Korn, E. L., & Gray, R. (2010) · Clinical Trials · doi:10.1177/1740774510369019 · Cited by 64
TGFβ1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors
Ruyck, K. D., Eijkeren, M. V., Claes, K., Bacher, K., Vral, A., Neve, W. D., & Thierens, H. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.03.047 · Cited by 59
Genotyping:The use of single nucleotide polymorphisms in the isolation of common disease genes
Riley, J. H., Allan, C. J., Lai, E., & Roses, A. D. (2000) · Pharmacogenomics · doi:10.1517/14622416.1.1.39 · Cited by 55
Mantz, C. A., Nautiyal, J., Awan, A., Kopnick, M., Ray, P., Kandel, G., NIEDERBERGER, C. S., Ignacio, L., Dawson, E., Fields, R. C., et al. (1999) · PubMed · Cited by 49
Green, H. E., Ross, G., Peacock, J., et al. (2002) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(02)00079-8 · Cited by 34
Psychological Aspects of Testis Cancer Therapy: A Prospective Study
Tamburini, M., Filiberti, A., Barbieri, A., Zanoni, F., Giorgio Pizzocaro, A., Barletta, L., & Ventafridda, V. (1989) · The Journal of Urology · doi:10.1016/s0022-5347(17)39133-4 · Cited by 28
Cited by
Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.09.042 · Cited by 2,802
Cornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.03.027 · Cited by 1,246
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977
Kishan, A. U., Ma, T. M., Lamb, J. M., Casado, M., Wilhalme, H., Low, D. A., Sheng, K., Sharma, S., Nickols, N. G., Pham, J., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.6558 · Cited by 323
Esteva, A., Feng, J., van der Wal, D., Huang, S.-C., Simko, J. P., DeVries, S., Chen, E., Schaeffer, E. M., Morgan, T. M., Sun, Y., et al. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00613-w · Cited by 217
Metadata
- Authors
- Michalski, J. M., Moughan, J., Purdy, J., Bosch, W., Bruner, D. W., Bahary, J.-P., Lau, H., Duclos, M., Parliament, M., Morton, G., Hamstra, D., Seider, M., Lock, M. I., Patel, M., Gay, H., Vigneault, E., Winter, K., & Sandler, H.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-06-14
- Volume
- 4
- Issue
- 6
- Pages
- e180039
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2791655860
- Cited by
- 356
- References
- 47
- FWCI
- 25.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.